Clinical Trials Logo

Chemotherapeutic Agent Toxicity clinical trials

View clinical trials related to Chemotherapeutic Agent Toxicity.

Filter by:

NCT ID: NCT00755313 Completed - Breast Cancer Clinical Trials

Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer

Start date: May 2007
Phase: N/A
Study type: Observational

RATIONALE: Gathering information over time from laboratory tests, imaging scans, and assessment tests may help doctors learn more about the side effects of chemotherapy and plan the best treatment. PURPOSE: This clinical trial is studying the effects of chemotherapy on the brain in women with newly diagnosed early-stage breast cancer.

NCT ID: NCT00754767 Completed - Breast Cancer Clinical Trials

L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer

Start date: June 2006
Phase: N/A
Study type: Interventional

RATIONALE: L-carnitine L-tartrate may prevent peripheral neuropathy caused by chemotherapy. PURPOSE: This randomized clinical trial is studying how well L-carnitine L-tartrate works in preventing peripheral neuropathy caused by chemotherapy in women with metastatic breast cancer.

NCT ID: NCT00751101 Terminated - Breast Cancer Clinical Trials

Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer

Start date: August 20, 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Nicotine patches may reduce hand-foot syndrome in patients receiving capecitabine for metastatic breast cancer. It is not yet known which nicotine patch regimen may be more effective in reducing hand-foot syndrome. PURPOSE: This randomized clinical trial is studying which schedule of using nicotine patches is more effective in reducing hand-foot syndrome in patients who are receiving capecitabine for metastatic breast cancer.

NCT ID: NCT00748215 Completed - Colorectal Cancer Clinical Trials

Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan

Start date: February 4, 2009
Phase: Phase 2
Study type: Interventional

RATIONALE: Calcium aluminosilicate anti-diarrheal (CASAD) may help treat and prevent diarrhea caused by irinotecan. It is not yet known whether CASAD is more effective than a placebo in treating and preventing diarrhea in patients receiving irinotecan. PURPOSE: This randomized phase II trial is studying CASAD to see how well it works compared with a placebo in treating and preventing diarrhea in patients with metastatic colorectal cancer receiving irinotecan.

NCT ID: NCT00728429 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Aerobic Exercise in Patients Receiving Chemotherapy for Cancer

Start date: June 2008
Phase: N/A
Study type: Interventional

RATIONALE: Aerobic exercise may help prevent side effects caused by chemotherapy and help improve heart health. PURPOSE: This randomized clinical trial is studying the side effects of aerobic exercise and to see how well it works in patients receiving chemotherapy for cancer.

NCT ID: NCT00727831 Completed - Lymphoma Clinical Trials

Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Start date: July 2008
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as methotrexate and leucovorin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Glucarpidase may help return the level of methotrexate in the blood to a safe range. Giving high-dose methotrexate together with glucarpidase and leucovorin may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of methotrexate when given together with glucarpidase and leucovorin in treating patients with newly diagnosed primary central nervous system lymphoma.

NCT ID: NCT00695032 Suspended - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors

Start date: October 2007
Phase: N/A
Study type: Interventional

RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is evaluating kidney damage in patients receiving cisplatin and ifosfamide for solid tumors.

NCT ID: NCT00662688 Terminated - Pancreatic Cancer Clinical Trials

Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer

PAM07
Start date: October 2007
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients being treated with chemotherapy. It is not yet known whether gemcitabine is more effective when given alone or together with dalteparin and/or capecitabine in treating patients with pancreatic cancer. PURPOSE: This randomized phase III trial is studying whether dalteparin prevents blood clots in patients with pancreatic cancer receiving treatment with different combinations of gemcitabine and capecitabine.

NCT ID: NCT00608738 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Using Whole-Person-Care Guide in Patients Receiving Care for Cancer or Complications From Cancer Treatment

Start date: July 2001
Phase: N/A
Study type: Interventional

RATIONALE: Gathering information about patients with cancer and cancer-related conditions may help doctors learn more about a patient's needs and help doctors plan the best treatment. PURPOSE: This clinical trial is studying how well a whole-person-care guide works in identifying patient needs in patients with cancer or complications from cancer treatment.

NCT ID: NCT00577798 Completed - Lymphoma Clinical Trials

Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin

Start date: January 1, 2008
Phase:
Study type: Observational

RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy. PURPOSE: This clinical trial is studying how well cardiac magnetic resonance imaging works in patients with newly diagnosed non-Hodgkin lymphoma or Hodgkin lymphoma receiving doxorubicin.